中山证券有限责任公司 关于 皓宸医疗科技股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 二〇二五年十一月 声 明 本声明所述的词语或简称与本核查意见"释义"部分所定义的词语或简称具 有相同的涵义。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购 管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变 动报告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公 司收购报告书》等相关法律、法规的规定，中山证券有限责任公司（以下简称"本 财务顾问"）作为信息披露义务人本次权益变动的财务顾问，按照行业公认的业 务标准、道德规范，本着诚实信用、勤勉尽责的原则，对本次权益变动的相关情 况和资料进行了核查，对信息披露义务人出具的《皓宸医疗科技股份有限公司详 式权益变动报告书》所披露的内容出具核查意见。 本财务顾问特做出以下声明： 一、本财务顾问依据的有关资料由信息披露义务人提供。信息披露义务人已 向本财务顾问作出承诺，保证其所提供的资料均为真实、准确、完整的原始书面 资料或副本资料，副本资料或复印件与其原始资料或原件一致，所有文件的签名、 印章均是真 ...

Core Viewpoint - Haocen Medical Technology Co., Ltd. has reported a significant decline in revenue and a drastic drop in net profit, alongside a court-ordered freeze on the equity of its key subsidiary, Delun Medical [1][2][6]. Financial Performance - For the first three quarters of 2025, Haocen Medical achieved a revenue of 527 million yuan, a year-on-year decrease of 17.0%, and a net loss attributable to shareholders of 26.41 million yuan, a decline of 295.7% [2][5]. - In Q3 2025, the company reported a revenue of 213 million yuan, down 15.7% year-on-year, and a net loss of 2.66 million yuan, a decrease of 120.5% [2]. Revenue Breakdown - The core issue behind the performance decline is attributed to the drop in the oral medical service segment, which constitutes 91.98% of total revenue. This segment saw a revenue decline of 17.39% in the first half of 2025 [3]. Legal and Asset Issues - The 51% equity stake in Delun Medical, a key subsidiary, has been frozen by the court due to a creditor's revocation dispute, with the freeze lasting for two years [6][8]. - The legal dispute stems from a loan agreement with Wenzhou Bank, where the creditor claims that the transfer of equity to another subsidiary adversely affected their ability to recover the debt [7][8]. Attempts at Financial Recovery - Haocen Medical has attempted various self-rescue measures, including asset auctions and loan applications, but these efforts have not yielded positive results [9]. - The company is currently seeking to negotiate debt resolution strategies with creditors, including debt reduction and restructuring, but has not made substantial progress [9].

Core Viewpoint - Haocen Medical (002622) has experienced a stock price increase of 3.9% to 3.46 CNY, with a total market capitalization of 2.906 billion CNY as of November 3, 2025. The company faces a legal dispute regarding the transfer of shares in its subsidiary, Delun Medical, which may pose operational risks despite not directly impacting current or future profits [1]. Group 1 - As of November 3, 2025, Haocen Medical's stock closed at 3.46 CNY, up 3.9% from the previous trading day, with a total market value of 2.906 billion CNY [1]. - The stock opened at 3.33 CNY, reached a high of 3.5 CNY, and a low of 3.31 CNY, with a trading volume of 1.58 billion CNY and a turnover rate of 5.53% [1]. - The company announced that it received a legal document from the Jilin City Chuanming District People's Court regarding a dispute over the revocation of share transfer rights [1]. Group 2 - The lawsuit involves Zhejiang Zheba Xianhu Enterprise Management Partnership (Limited Partnership) as the plaintiff, with Haocen Medical, its wholly-owned subsidiary Zhiyu Medical, and its controlling subsidiary Delun Medical as defendants [1]. - The court has ruled to freeze 51% of Delun Medical's shares held by Zhiyu Medical, corresponding to an investment amount of 26.52 million CNY, with a freeze period of two years [1]. - Delun Medical accounted for 89.78% of the company's total revenue in 2024, indicating its significant role in the company's financial performance [1].

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-029 皓宸医疗科技股份有限公司 关于控股孙公司收到法院传票及《民事裁定书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼阶段：收到传票，尚未开庭审理。 2、上市公司所处的当事人地位：皓宸医疗科技股份有限公司（以下简称"公司"）、 全资子公司植钰医疗投资有限公司（以下简称"植钰医疗"）及其控股子公司广东德伦医 疗集团有限公司（以下简称"德伦医疗"）为被告。 3、涉案的金额：植钰医疗持有的德伦医疗股权，持股比例为 51%，对应出资额为 2,652 万元。 4、对上市公司损益产生的影响：本次诉讼所涉及为债权人转让撤销权纠纷，其判决 结果预计不会对公司本期利润或期后利润造成直接影响。若法院对该案采取进一步措施， 则可能存在被司法处置的风险，可能对公司及子公司的生产经营产生一定的影响。 公司于 2025 年 10 月 30 日收到控股孙公司德伦医疗转发的吉林市船营区人民 法院出具的案号（2025）吉 0204 民初 4757 号《传票》《民事裁定书》《民事起诉 状》 ...

Core Viewpoint - Haocen Medical, established in 1998 and listed in 2011, operates in the medical services sector with a focus on oral healthcare, but its financial performance lags behind industry leaders [1][2]. Financial Performance - For Q3 2025, Haocen Medical reported revenue of 527 million yuan, ranking 14th in the industry, significantly lower than the top player Aier Eye Hospital's 17.48 billion yuan and second-place Meinian Health's 6.93 billion yuan [2]. - The company's main revenue source is oral medical services, generating 288 million yuan, accounting for 91.98% of total revenue, while industrial switch products contributed 24.11 million yuan (7.69%) and other income was 1.04 million yuan (0.33%) [2]. - The net profit for the same period was -31.03 million yuan, placing it 13th in the industry, far behind Aier Eye Hospital's 3.367 billion yuan and Tongce Medical's 616 million yuan [2]. Financial Ratios - As of Q3 2025, Haocen Medical's debt-to-asset ratio was 71.72%, up from 68.55% year-on-year and above the industry average of 46.74% [3]. - The gross profit margin stood at 47.72%, slightly down from 47.97% year-on-year but still above the industry average of 31.10% [3]. Management and Shareholder Information - The chairman, Lu Lu, has a salary of 1.2 million yuan for 2024, unchanged from 2023 [4]. - As of September 30, 2025, the number of A-share shareholders decreased by 4.97% to 46,200, while the average number of shares held per shareholder increased by 5.23% to 18,200 [5].

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-027 经与会董事认真审议并表决，通过了以下议案： 一、审议通过《关于 2025 年第三季度报告的议案》 表决情况：同意 7 票，反对 0 票，弃权 0 票； 表决结果：通过。 本议案已经公司审计委员会审议并取得了明确同意的意见。 皓宸医疗科技股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第十六次会 议于 2025 年 10 月 30 日上午 10:00 在公司会议室以现场结合通讯表决方式召开。 召开本次会议的通知已于 2025 年 10 月 19 日以电话、电子邮件等方式通知了各 位董事，会议应参加表决董事 7 名，实际参加表决董事 7 名。此次会议的召集、 召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相关法律、法 规的规定，合法有效。 1、《皓宸医疗科技股份有限公司第五届董事会第十六次会议决议》。 特此公告。 皓宸医疗科技股份有限公司董事会 二〇二五年十月三十日 《2025 ...

Core Insights - Haocen Medical reported a decline in revenue and an increase in net loss for the third quarter and the first three quarters of the year [1] Financial Performance - In Q3, the company achieved operating revenue of 213.26 million yuan, a year-on-year decrease of 15.72% [1] - The net loss attributable to shareholders for Q3 was 2.66 million yuan, a year-on-year decrease of 120.54% [1] - For the first three quarters, the company reported operating revenue of 526.89 million yuan, a year-on-year decrease of 17.03% [1] - The net loss attributable to shareholders for the first three quarters was 26.41 million yuan, a year-on-year decrease of 295.68% [1]

Core Viewpoint - Haocen Medical (002622.SZ) reported a decline in revenue and net profit for the first three quarters of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 527 million yuan, representing a year-on-year decrease of 17.03% [1] - The net profit attributable to shareholders was -26.41 million yuan, indicating a loss [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -24.52 million yuan [1] - The basic earnings per share were -0.0314 yuan [1]

Group 1 - The core point of the article is that Haocen Medical (SZ 002622) held its 16th meeting of the 5th Board of Directors on October 30, 2025, to review the proposal for the Q3 2025 report [1] - For the first half of 2025, Haocen Medical's revenue composition is as follows: 91.98% from the dental industry, 7.69% from switches, and 0.33% from leasing [1] - As of the report date, Haocen Medical has a market capitalization of 2.7 billion yuan [1]

Group 1 - The core point of the article is that Haocen Medical reported a significant decline in revenue and incurred a net loss in the third quarter of 2025 [1] - For the first three quarters of 2025, the company's revenue was approximately 527 million yuan, representing a year-on-year decrease of 17.03% [1] - The net profit attributable to shareholders was a loss of approximately 26.41 million yuan, with basic earnings per share reflecting a loss of 0.0314 yuan [1] Group 2 - As of the report, Haocen Medical's market capitalization stands at 2.7 billion yuan [2]